Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVDL NASDAQ:CALA NASDAQ:MIRM NYSE:MNK NASDAQ:OGI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVDLAvadel Pharmaceuticals$15.19-1.4%$12.80$6.38▼$16.66$1.50B1.571.41 million shs1.42 million shsCALACalithera Biosciences$0.00$0.00▼$0.05N/A-2.558,748 shs64 shsMIRMMirum Pharmaceuticals$74.19-0.2%$62.66$36.86▼$78.10$3.73B0.92701,574 shs436,282 shsMNKMallinckrodt$0.34$0.75▼$6.42$1.58MN/A2.62 million shs39,227 shsOGIOrganigram Global$1.71+3.0%$1.53$0.85▼$2.00$222.53M1.49709,171 shs666,707 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVDLAvadel Pharmaceuticals-1.36%-1.24%+10.96%+62.11%+10.88%CALACalithera Biosciences0.00%0.00%-90.00%0.00%-99.80%MIRMMirum Pharmaceuticals-0.16%-4.13%+9.22%+46.33%+80.42%MNKMallinckrodt0.00%0.00%0.00%0.00%0.00%OGIOrganigram Global+3.01%+4.27%+19.58%+24.82%-8.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVDLAvadel Pharmaceuticals$15.19-1.4%$12.80$6.38▼$16.66$1.50B1.571.41 million shs1.42 million shsCALACalithera Biosciences$0.00$0.00▼$0.05N/A-2.558,748 shs64 shsMIRMMirum Pharmaceuticals$74.19-0.2%$62.66$36.86▼$78.10$3.73B0.92701,574 shs436,282 shsMNKMallinckrodt$0.34$0.75▼$6.42$1.58MN/A2.62 million shs39,227 shsOGIOrganigram Global$1.71+3.0%$1.53$0.85▼$2.00$222.53M1.49709,171 shs666,707 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVDLAvadel Pharmaceuticals-1.36%-1.24%+10.96%+62.11%+10.88%CALACalithera Biosciences0.00%0.00%-90.00%0.00%-99.80%MIRMMirum Pharmaceuticals-0.16%-4.13%+9.22%+46.33%+80.42%MNKMallinckrodt0.00%0.00%0.00%0.00%0.00%OGIOrganigram Global+3.01%+4.27%+19.58%+24.82%-8.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVDLAvadel Pharmaceuticals 3.11Buy$20.8637.31% UpsideCALACalithera Biosciences 0.00N/AN/AN/AMIRMMirum Pharmaceuticals 3.11Buy$74.440.34% UpsideMNKMallinckrodt 0.00N/AN/AN/AOGIOrganigram Global 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CALA, MIRM, OGI, MNK, and AVDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025MIRMMirum PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$53.00 ➝ $77.009/5/2025AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$24.00 ➝ $36.009/3/2025AVDLAvadel PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold9/3/2025AVDLAvadel PharmaceuticalsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/2/2025AVDLAvadel PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageEqual Weight$16.008/21/2025AVDLAvadel PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $20.008/11/2025MIRMMirum PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$89.008/8/2025AVDLAvadel PharmaceuticalsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/8/2025AVDLAvadel PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/8/2025AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.00 ➝ $24.008/8/2025MIRMMirum PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$77.00 ➝ $89.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVDLAvadel Pharmaceuticals$169.12M8.72N/AN/A$0.77 per share19.73CALACalithera BiosciencesN/AN/AN/AN/AN/AN/AMIRMMirum Pharmaceuticals$336.89M11.06N/AN/A$4.70 per share15.79MNKMallinckrodtN/AN/AN/AN/A$47.48 per shareN/AOGIOrganigram Global$223.82M1.02N/AN/A$2.07 per share0.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVDLAvadel Pharmaceuticals-$48.83M-$0.03N/A253.17N/A-1.32%-3.73%-1.73%11/11/2025 (Estimated)CALACalithera Biosciences-$39.65MN/A0.00N/AN/AN/AN/AN/AN/AMIRMMirum Pharmaceuticals-$87.94M-$1.21N/AN/AN/A-13.65%-24.76%-8.50%11/11/2025 (Estimated)MNKMallinckrodtN/A-$116.19N/AN/AN/A-82.59%20.32%2.49%N/AOGIOrganigram Global-$33.39M$0.0534.21N/AN/A2.86%-8.19%-5.79%N/ALatest CALA, MIRM, OGI, MNK, and AVDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q3 2025OGIOrganigram Global-$0.01-$0.03-$0.02-$0.03$68.04 million$50.49 million8/7/2025Q2 2025AVDLAvadel Pharmaceuticals$0.02$0.10+$0.08$0.10$60.28 million$68.13 million8/6/2025Q2 2025MIRMMirum Pharmaceuticals-$0.31-$0.12+$0.19-$0.12$107.91 million$127.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/AMNKMallinckrodtN/AN/AN/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVDLAvadel PharmaceuticalsN/A2.792.38CALACalithera BiosciencesN/AN/AN/AMIRMMirum Pharmaceuticals1.213.132.97MNKMallinckrodt1.180.570.31OGIOrganigram GlobalN/A2.591.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVDLAvadel Pharmaceuticals69.19%CALACalithera BiosciencesN/AMIRMMirum PharmaceuticalsN/AMNKMallinckrodt83.74%OGIOrganigram Global34.63%Insider OwnershipCompanyInsider OwnershipAVDLAvadel Pharmaceuticals5.20%CALACalithera Biosciences6.60%MIRMMirum Pharmaceuticals22.87%MNKMallinckrodt0.30%OGIOrganigram Global0.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVDLAvadel Pharmaceuticals7097.10 million92.05 millionOptionableCALACalithera Biosciences604.87 million4.55 millionNot OptionableMIRMMirum Pharmaceuticals14050.24 million38.75 millionOptionableMNKMallinckrodt2,70013.17 million13.13 millionNot OptionableOGIOrganigram Global860134.05 million133.93 millionOptionableCALA, MIRM, OGI, MNK, and AVDL HeadlinesRecent News About These CompaniesOrganigram Global (NASDAQ:OGI) Stock Price Down 0.6% - Here's WhySeptember 10, 2025 | marketbeat.comOrganigram’s Report Highlights Cannabis as Key Economic Driver in CanadaSeptember 2, 2025 | tipranks.comOrganigram Global Releases Landmark Report: Legal Cannabis Added $16B to Canada’s GDP in 2024September 2, 2025 | financialpost.comFOrganigram Global Releases Landmark Report: Legal Cannabis Added $16B to Canada's GDP in 2024September 2, 2025 | businesswire.comFY2025 EPS Estimate for Organigram Global Reduced by AnalystAugust 19, 2025 | marketbeat.comOrganigram Global (NASDAQ:OGI) Announces Earnings ResultsAugust 17, 2025 | marketbeat.comAtb Cap Markets Issues Pessimistic Forecast for OGI EarningsAugust 17, 2025 | marketbeat.comOGI FY2025 EPS Forecast Reduced by Alliance Global PartnersAugust 17, 2025 | marketbeat.comOrganigram Global (NASDAQ:OGI) Cut to Sell at Wall Street ZenAugust 17, 2025 | marketbeat.comOrganigram Global Inc. (OGI) Q3 2025 Earnings Call TranscriptAugust 13, 2025 | seekingalpha.comOrganigram reports Q3 revenue $70.8M, consensus $68.04MAugust 13, 2025 | msn.comOrganigram Posts Wider Loss, Eyes Profitability In Near TermAugust 13, 2025 | benzinga.comOrganiGram (OGI) Reports Q3 Loss, Beats Revenue EstimatesAugust 13, 2025 | zacks.comOrganigram Reports Record Third Quarter Fiscal 2025 ResultsAugust 13, 2025 | financialpost.comFOrganigram Global Inc. (OGI) Expands Into U.S. THC Beverage Market Across 25 StatesAugust 2, 2025 | msn.comOrganigram to Report Third Quarter Fiscal 2025 Results on August 13, 2025August 1, 2025 | financialpost.comFOrganigram Global Inc. (OGI) Stock Price Today - WSJJuly 15, 2025 | wsj.comShareholders in Organigram Global (TSE:OGI) are in the red if they invested five years agoJuly 9, 2025 | finance.yahoo.comOrganigram Expands U.S. Presence with Hemp-Derived THC Beverage LaunchJuly 8, 2025 | tipranks.comOrganigram Global Scales U.S. Presence with Collective Project Direct-to-Consumer Launch in 25 States and Expansion of Hemp-Derived THC Beverage PortfolioJuly 8, 2025 | financialpost.comFOrganigram Global Scales U.S. Presence with Collective Project Direct-to-Consumer Launch in 25 States and Expansion of Hemp-Derived THC Beverage PortfolioJuly 8, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Renaissance Hedge Fund Adds NVIDIA, Follows Buffett Into UNHBy Leo Miller | August 20, 2025Dueling Insider Moves: Heavy Buying Here, Big Selling ThereBy Leo Miller | September 2, 2025Insiders Sell These High-Quality Stocks: Why Investors Shouldn’tBy Thomas Hughes | September 8, 20253 Hot Tech Stocks With Bullish Charts and Ample UpsideBy Thomas Hughes | September 15, 2025CALA, MIRM, OGI, MNK, and AVDL Company DescriptionsAvadel Pharmaceuticals NASDAQ:AVDL$15.19 -0.21 (-1.36%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$15.41 +0.22 (+1.45%) As of 08:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Calithera Biosciences NASDAQ:CALACalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Mirum Pharmaceuticals NASDAQ:MIRM$74.19 -0.12 (-0.16%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$73.72 -0.47 (-0.63%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Mallinckrodt NYSE:MNKMallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.Organigram Global NASDAQ:OGI$1.71 +0.05 (+3.01%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$1.70 0.00 (-0.29%) As of 08:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
